Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study.

By A. Sturdza, R. Pötter, L. Fokdal, C. Haie-meder, L. Tan, R. Mazeron, P. Petric, B. Segedin, Ina Jurgenliemk-Schulz, C. Nomden and 14 more. Radiotherapy and Oncology, 2016

661 citations recorded by the source corpus.

Subfields: Obstetrics and Gynecology, Radiation, Surgery

View Paper: https://www.semanticscholar.org/paper/f319803d707bac3b6d20063d78aa6edd871afc3a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Obstetrics and Gynecology

1. Remi A. Nout
2. N. Colombo
3. C. Marth
4. A. González-Martín

Citations in the corpus

• The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies (2018, background): “The 3-year local and pelvic control rates reached 98–100% and 96%, respectively, for FIGO stage IB1 and IB2 disease, and 93–96% and 89–91%, respectively, for stage IIB disease [12,22].”
• Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, background): “A recently published multicentre cohort study (RetroEMBRACE) demonstrated excellent local control rates of 93% and 79% for patients with FIGO stage IIB and IIIB disease, respectively, at 3 years [37].”
• Cervical cancer: A global health crisis (2017, background): “With state-of-the-art staging and treatment, the 3-year local control rate for patients with early-stage and advanced stage cervical cancer is 87% to 95% and 74% to 85%, respectively.(15,16) For all stages combined, the 3-year to 5-year survival rate from cervical cancer for many underdeveloped coun”